ライフサイエンスコーパス: injected dose

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 injected dose (range, 0.64-12.41 percentage injected dose).

2 carbon nanotubes at a low dose (17 mg l(-1) injected dose).

3 e was a median 102% (range, 78%-113%) of the injected dose.

4 organ region-of-interest data normalized by injected dose.

5 h after injection, with uptake of 1% of the injected dose.

6 rate density (NECRD) curves as a function of injected dose.

7 and should be used in studies limited by low injected dose.

8 rsed when corrected as a percentage of total injected dose (0.022% versus 0.017%, P = .003).

9 of brain tissue +/- 0.30 or 0.00019% of the injected dose 1 week after dosing.

10 of brain tissue +/- 0.10 or 0.00011% of the injected dose) 20 weeks after dosing.

11 basis of the data for these 4 patients (mean injected dose, 231 MBq), the radiation exposure of a (68

12 ddition to blood activity and PET/CT system, injected dose affected quantification of arterial 18F-Na

13 in normal rats showed 72.1+/-6.4 percentage injected dose and 88.6+/-6.2 percentage injected dose, r

14 tracer uptake in the pancreas normalized by injected dose and body weight.

15 ctivity for calculation of SLN percentage of injected dose and extraction.

16 wed high renal excretion (83.2% +/- 7.3%) of injected dose and rapid blood clearance.

17 n steps, corrected for radiotracer decay and injected dose, and fitted to a bicompartmental model.

18 d lesion detectability, reduced scan time or injected dose, and more accurate and precise lesion upta

19 Therefore, blood activity, injected dose, and PET/CT system should be considered to

20 8F-NaF uptake is affected by blood activity, injected dose, and PET/CT system.

21 comparable in the total duration of seizure, injected dose, and time from the injection to the image

22 a t(1/2) of 24 h and accumulated to 1.7% of injected dose at 24 h following i.v. delivery.

23 Uptake of CMICE-013 was 1.5% of the injected dose at rest and increased more rapidly with in

24 apable of increasing the efficacy of a given injected dose by improving both pharmacokinetic profile

25 ated whether blood activity, renal function, injected dose, circulating time, and PET/CT system affec

26 h a standard rat brain atlas, and percentage injected dose/cm(3) and binding potential (simplified re

27 nfirmed by radiochromatography and was 0.05% injected dose/cm(3) as measured by PET/CT.

28 olabeled 28H1 in inflamed joints (percentage injected dose) correlated with the arthritis score (Spea

29 vo antibody uptake value (AUV) normalized by injected dose, effective half-life, and injection-scan t

30 he 14-min acquisition or 125.8-MBq (3.4-mCi) injected dose for the 10-min acquisition.

31 vel would correspond to a 92.5-MBq (2.5-mCi) injected dose for the 14-min acquisition or 125.8-MBq (3

32 systems provide an opportunity to lower the injected doses for SPECT myocardial perfusion imaging (M

33 ulation of (99m)Tc-SPIONs (as the percentage injected dose/g [%ID/g]) in the SLN was 100 %ID/g, where

34 .1% injected dose/g after 24 h; 81% +/- 7.5% injected dose/g after 1 wk) after intraperitoneal admini

35 ated predominantly in tumors (32.8% +/- 8.1% injected dose/g after 24 h; 81% +/- 7.5% injected dose/g

36 e for *I-SGMIB-Nanobody was 24.50% +/- 9.89% injected dose/g at 2 h, 2- to 4-fold higher than observe

37 take in thyroid, salivary glands (percentage injected dose/g at 30 min, 563 +/- 140 and 32 +/- 9, res

38 /- 9, respectively), and stomach (percentage injected dose/g at 90 min, 68 +/- 21).

39 st melanoma uptake (22.3 +/- 1.72 percentage injected dose/g) at 2 h after injection.

40 take to a level (approximately 10 percentage injected dose/g) comparable to that obtained with radiom

41 owed tumor uptake after 3 d (19.7% +/- 17.0% injected dose/g) comparable to that of (111)In-DTPA-MN-1

42 e infarct area; quantitative uptake (percent injected dose/g) was highest at 2 weeks (2.75 +/- 0.46%)

43 77)Lu-tetrazine tumor uptake (6.9 percentage injected dose/g) was observed with low renal retention,

44 High tumor uptake (10.11% +/- 1.67% injected dose/g, n = 5) was detected at 60 min after inj

45 ol mice (5.17% +/- 1.18% vs. 2.41% +/- 0.34% injected dose/g, P = 0.02), as corroborated by imaging.

46 2.59%, 8.36% +/- 2.15%, and 3.09% +/- 0.58% injected dose/g, respectively).

47 on, reaching 9.1% +/- 0.5% and 7.6% +/- 1.2% injected dose/g, respectively, at 60 min after injection

48 ty, ranging from 167 +/- 23% to 417 +/- 109% injected dose/gram (% ID/g) after injection of the (211)

49 ides was 4.47% +/- 1.21% and 4.56% +/- 0.64% injected dose/gram (%ID/g), compared with a low-affinity

50 up to 59% in U87MG xenografts [2.10+/-0.14% injected dose/gram (ID/g) in the 95 mg/kg group and 3.12

51 fforded a tumor uptake of approximately 10 % injected dose/gram, owing to a long circulation half-lif

52 the mean (111)In-panitumumab uptake of 29.6% injected dose (ID) per gram +/- 2.2 (standard error of t

53 The highest concentration of the injected dose (ID) was found in the fetal kidney (0.0161

54 10 mug of (89)Zr-RO5323441 was 8.2% +/- 1.7% injected dose (ID)/cm(3) at 144 h after injection, and i

55 ultrahigh accumulation of approximately 30% injected dose (ID)/g in 4T1 murine breast tumors in Balb

56 al PET (postoperative day 4), and percentage injected dose (%ID) as a parameter of T-cell infiltratio

57 an 87% +/- 3% decrease in the percentage of injected dose (%ID) in all identified disease sites.

58 5.74 +/- 0.54, and 5.34 +/- 0.19 percentage injected dose (%ID) per gram at 1, 2, 3, and 4 h, respec

59 mor uptake; at 2 h, 5.94 +/- 1.83 percentage injected dose (%ID) per gram was observed in B16F10 tumo

60 SPECT-quantified percentage injected dose (%ID) was calculated and compared with the

61 in the saline control group (mean = 4.43% of injected dose [ID] per gram of tissue vs 0.99% of inject

62 take in the 231 G521R ER xenografts (percent injected dose [ID] per gram, 0.49 +/- 0.042), which was

63 < .0001) after human MSC injection (0.0054% injected dose [ID]/g +/- 0.0007 [standard deviation]) co

64 tissue gadolinium levels at 24 hours (<3.9% injected dose [ID]/g +/- 0.6) and 10-fold lower levels a

65 acer exhibited good tumor localization (3.4% injected dose [ID]/g +/- 1.0 [standard deviation] at 1 h

66 s) and accumulated in the liver (mean, 33.4% injected dose [ID]/g +/- 13.7 [standard deviation] at 60

67 on (70.3 +/- 1.3 and 73.8 +/- 3.0 percentage injected dose [%ID], respectively, at 90 min after injec

68 h after injection (18.13 +/- 1.73 percentage injected dose [%ID]/g and 11.81 +/- 2.05 %ID/g, respecti

69 rs (2.4 +/- 0.17 vs. 1.6 +/- 0.14 percentage injected dose [%ID]/g at 2 h after injection, P = 0.006)

70 high peak uptake (836.6 +/- 86.6 percentage injected dose [%ID]/g) compared with background liver (2

71 higher for (18)F-FET (3.5 +/- 0.8 percentage injected dose [%ID]/g) than for (64)Cu-NOTA-AE105 (1.2 +

72 in isothiocyanate (10.86 +/- 0.94 percentage injected dose [%ID]/g), IRDye800CW (13.66 +/- 3.73 %ID/g

73 min after injection (9.2 +/- 2.0 percentage injected dose [%ID]/g).

74 : 5.44 +/- 0.37 vs. 3.33 +/- 0.20 percentage injected dose [%ID]/g, P < 0.05).

75 Percentage injected doses (%IDs) corrected for radioactive decay in

76 F-NaF uptake based on the ratio of (18)F-NaF injected dose in (18)F(-)/(18)F-FDG PET/CT.

77 RAGE uptake as percentage injected dose in diabetic ApoE(-/-) mice (1.39 +/- 0.16

78 ein binding, red cell uptake, and percentage injected dose in the urine at 30 and 180 min were determ

79 ein binding, red cell uptake, and percentage injected dose in the urine at 30 and 180 min were determ

80 no significant difference in the percentage injected dose in the urine at 30 min (P = 0.24) and at 3

81 In normal rats, the percentage injected dose in urine at 10 and 60 min for both prepara

82 Approximately 8% of the injected dose is rapidly cleared as a low-molecular-weig

83 ulsion (AUClast in plasma - 20.2+/-1.86min*%/injected dose/ml) and solution form (AUClast in plasma -

84 tem (AUClast in plasma - 263.89+/-21.81min*%/injected dose/ml) as compared to the cationic nanoemulsi

85 n form (AUClast in plasma - 44.9+/-1.24min*%/injected dose/ml) respectively.

86 tial concentration in blood was 22.4% of the injected dose/mL, and annexin A5-CCPM was mainly distrib

87 r vessels was achieved using a ~6-fold lower injected dose of (12,1) and (11,3) SWNTs (~3 mug per mou

88 After 10 minutes, 4.5% +/- 1.1% of the injected dose of (213)Bi was delivered per gram of tumor

89 umor-absorbed dose of 43.8 Gy per millicurie injected dose of (90)Y, with tumor-to-normal organ dose

90 With an injected dose of 10 mCi (370 MBq) and a 1-hour voiding i

91 he interstitial fluorescence saturated at an injected dose of 20mg/kg.

92 y bolus plus constant infusion, with a total injected dose of 361 +/- 20 MBq.

93 After 24 h, 27.3% +/- 2.8% of the injected dose of activity was delivered per gram (% ID/g

94 ly entered the monkey brain (peak percentage injected dose of approximately 6.6%), and its brain dist

95 The percentage injected dose of CMICE-013 taken up by the heart was gre

96 rend correlated with change in percentage of injected dose of FDG in tumor for all groups (R(2) = 0.8

97 tumor volume, calculation of the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in

98 ed, ex vivo images acquired, and the percent injected dose of MPI per gram (%ID/g) determined, follow

99 oved and counted to calculate the percentage injected dose of RAGE per gram of tissue, followed by hi

100 Injected doses of 200ng/mg body weight led to mortality

101 (0.06 +/- 0.01 vs. 0.16 +/- 0.05 percentage injected dose, P < 0.01), PET imaging (maximum SUV, 3.8

102 .02% vs. 0.25% +/- 0.04% and 0.24% +/- 0.03% injected dose, P < 0.05), with retention of all 3 tracer

103 diastolic volume from 1 to 12 wk (percentage injected dose per centimeter cubed, 0.15 +/- 0.07 vs. 0.

104 teadily increasing concentrations, up to 11% injected dose per cm(3), are observed in the tumor over

105 (18)F-FLT uptake was reported in percentage injected dose per cubed centimeter by drawing regions of

106 in the pulmonary LNs (6.8 +/- 1.1 percentage injected dose per cubic centimeter [%ID/cm(3)]) 24 h aft

107 sing tumors, reaching 5.6 +/- 1.2 percentage injected dose per cubic centimeter at 40-60 min and rapi

108 (0.87 +/- 0.06 vs. 1.11 +/- 0.09 percentage injected dose per cubic centimeter in control group, P <

109 data analysis was performed using percentage injected dose per cubic centimeter of tissue (%ID/cm(3))

110 average concentration, 30.1% +/- 4.6% of the injected dose per cubic centimeter).

111 I rats or sham-operated controls (percentage injected dose per cubic centimeter, 0.20 +/- 0.05 vs. 0.

112 eduction in aortic tracer uptake (percentage injected dose per cubic centimeter, 0.95 +/- 0.04 vs. 1.

113 the non-targeted w-MWNT in vivo reaching ~2% injected dose per g of brain (%ID/g) within the first ho

114 A-UBI29-41 peaked at 3.8 +/- 0.91 percentage injected dose per gram (%ID) at 120 min, and 88 +/- 5.2

115 with a mean uptake of 2.5 +/- 0.3 percentage injected dose per gram (%ID/g) (mean +/- SEM) 4 h after

116 her tissue, peaking at 100 +/- 21 percentage injected dose per gram (%ID/g) 24 h after injection, a v

117 11)In had a remarkable tumor uptake of 43.2% injected dose per gram (%ID/g) 72 hours after tail vein

118 ce of approximately 1.10 +/- 0.20 percentage injected dose per gram (%ID/g) and 0.90 +/- 0.12 %ID/g,

119 peak tumor uptake of 12.00+/-3.20 percentage injected dose per gram (%ID/g) at 1 h after injection.

120 lioma xenografts was 6.2 (+/-1.3) percentage injected dose per gram (%ID/g) at 1 h and 4.9 (+/-0.62)

121 ith tumor uptake of 0.76 +/- 0.09 percentage injected dose per gram (%ID/g) at 30 min after injection

122 adily increased with time to 24.1 percentage injected dose per gram (%ID/g) at 48 h.

123 32.17 +/- 7.99 and 15.79 +/- 6.44 percentage injected dose per gram (%ID/g) at 5 and 24 h, respective

124 vel of 3.4 +/- 0.1 to 9.5 +/- 0.4 percentage injected dose per gram (%ID/g) at 6 h after injection on

125 ultimately reaching 22.3 +/- 6.3 percentage injected dose per gram (%ID/g) at 72 h after injection.

126 e of (111)In-28H1 ranged from 2.2 percentage injected dose per gram (%ID/g) in noninflamed joints to

127 explanted to quantitatively measure percent injected dose per gram (%ID/g) MPI uptake.

128 of 12.4 +/- 2.3 and 22.7 +/- 3.3 percentage injected dose per gram (%ID/g) of tissue, respectively,

129 m 23 +/- 15, 8 +/- 4, and 2 +/- 1 percentage injected dose per gram (%ID/g) to 11 +/- 11 (P < 0.001),

130 ersus control groups (3.0 +/- 0.0 percentage injected dose per gram (%ID/g) vs. 21.0 +/- 3.4 %ID/g, r

131 tumor uptake of approximately 40 percentage injected dose per gram (%ID/g) was observed at 3-4 d aft

132 Compound [(125)I]3 demonstrated 8.8 +/- 4.7% injected dose per gram (%ID/g) within PSMA(+) PC-3 PIP t

133 ion, tumor uptake was 4.4 +/- 0.8 percentage injected dose per gram (%ID/g), 5.6 +/- 1.6 %ID/g, and 7

134 bited 2.3 +/- 0.6 and 1.3 +/- 0.4 percentage injected dose per gram (%ID/g), respectively, in BxPC3 x

135 9, 22.1 +/- 1.9, and 22.7 +/- 1.7 percentage injected dose per gram (%ID/g), respectively.

136 d from 5.3 and 3.5 to 3.0 and 2.4 percentage injected dose per gram (%ID/g), respectively.

137 r injection, tumor uptake was 4.4 percentage injected dose per gram (%ID/g), significantly greater th

138 hanced tumor uptake [42.9 +/- 9.5 percentage injected dose per gram (%ID/g); n = 4] and tumor-to-back

139 rom the blood, with levels decreasing to <1% injected dose per gram (ID/g) by 16 hours.

140 ts exhibited tumor uptake of 0.58% +/- 0.06% injected dose per gram (ID/g) for [(125)I]11a and 1.12%

141 Tumor uptake of 8.82% injected dose per gram (ID/g) was seen at 4 hours postin

142 (111)In-HSG-peptide 2.6-fold [13% versus 5% injected dose per gram (ID/g)] and enhanced tumor to blo

143 ecific tumor uptake of 11 and 2.3 percentage injected dose per gram 24 h after injection, respectivel

144 lower tumor uptake (3.62 +/- 1.18 percentage injected dose per gram [%ID/g] 22Rv1xPSCA, 3.63 +/- 0.59

145 ifference between PD-L1-positive (percentage injected dose per gram [%ID/g] = 2.56 +/- 0.33) and -neg

146 tive PC-3 xenografts in mice (4.4 percentage injected dose per gram [%ID/g] [(99m)Tc-SARNC4] to 12.0

147 ulted in high tumor uptake (17.56 percentage injected dose per gram [%ID/g] at 4 h after injection),

148 enografts (SK-RC-52, 31.5 +/- 9.6 percentage injected dose per gram [%ID/g] at 72 h after injection).

149 knockdown of hCtr1 (4.02 +/- 0.31 percentage injected dose per gram [%ID/g] in Lenti-hCtr1-shRNA-PC-3

150 organs except the kidneys (7.8 percentage of injected dose per gram [%ID/g]) and as high as 15.2 %ID/

151 for (111)In-3BP-227 (8.4 +/- 3.1 percentage injected dose per gram [%ID/g]) and at 3 h after injecti

152 in arthritic ankles (2.2 +/- 0.2 percentage injected dose per gram [%ID/g]) and forepaws (2.1 +/- 0.

153 was highest in H441 (6.2 +/- 1.1 percentage injected dose per gram [%ID/g]) and lowest in Calu-1 (2.

154 at 1 h after injection (>300-400 percentage injected dose per gram [%ID/g]) but decreased by 2-3-fol

155 hest uptake of (111)In-bsRICs (7.8% +/- 2.1% injected dose per gram [%ID/g]) in BT-474 human breast c

156 lent tracers ( approximately 0.60 percentage injected dose per gram [%ID/g]) than for trivalent trace

157 correlated with measured uptake (percentage injected dose per gram [%ID/g]) values at 60 min.

158 EM1 tumors at 4 h (153.2 +/- 22.2 percentage injected dose per gram [%ID/g]), 24 h (127.1 +/- 42.9 %I

159 tumors after 24 h (20.35 +/- 7.50 percentage injected dose per gram [%ID/g]), 48 h (22.82 +/- 3.58 %I

160 -positive) was high (36.8 +/- 7.8 percentage injected dose per gram [%ID/g]), whereas uptake in MKN45

161 n after injection (26.35 +/- 1.52 percentage injected dose per gram [%ID/g]).

162 0 mug/mouse or less (13.5 +/- 5.2 percentage injected dose per gram [%ID/g]).

163 , 48, 96, and 144 h (34.4 +/- 3.2 percentage injected dose per gram [%ID/g], 38.0 +/- 6.2 %ID/g, 40.4

164 l (1 h: DX3purobeta6, 2.3 +/- 0.2 percentage injected dose per gram [%ID/g]; DX3purobeta6/DX3puro rat

165 . 3.88 +/- 1.00 vs. 2.36 +/- 1.25 percentage injected dose per gram [%ID/g]; P < 0.0001).

166 F-FAC was observed (6.98 +/- 0.43 percentage injected dose per gram [%ID/g]; tumor-to-normal ratio, 1

167 mor xenografts of approximately 6 percentage injected dose per gram and good tumor retention for at l

168 f (18)F-FPPRGD2 was quantified by percentage-injected dose per gram and target-to- BACKGROUND: =0.003

169 11)In-DOTA-Z09591 was 7.2 +/- 2.4 percentage injected dose per gram and the tumor-to-blood ratio was

170 x) was 24.94% +/- 4.58% and 10.53% +/- 1.11% injected dose per gram at 0.5 and 24 h after injection,

171 n LNCaP xenografts ranged from 9.3% to 12.4% injected dose per gram at 1 h after injection and from 7

172 red rapidly from the blood (<0.07 percentage injected dose per gram at 1 h after injection), mainly v

173 0.3, 3.4 +/- 0.3, and 2.4 +/- 0.3 percentage injected dose per gram at 1, 4, 15, and 36 h after injec

174 g 5.85 +/- 0.79 and 8.13 +/- 1.46 percentage injected dose per gram at 10 and 60 min, respectively.

175 itutively expresses ACE, was 15.2 percentage injected dose per gram at 10 min after injection and was

176 significant pancreas uptake (7.37 percentage injected dose per gram at 15 min), most likely due to th

177 sitive LNCaP tumors (45.8 +/- 8.0 percentage injected dose per gram at 168 h after injection), wherea

178 significantly lower (6.6 +/- 1.3 percentage injected dose per gram at 168 h after injection).

179 19.05 +/- 5.04 and 18.6 +/- 3.56 percentage injected dose per gram at 2 and 4 h after injection, res

180 a high initial brain uptake (6.45 percentage injected dose per gram at 2 min) and rapid brain washout

181 d in the best uptake (8.2 +/- 1.7 percentage injected dose per gram at 20 h after injection) and tumo

182 ze over time, reaching around 5.0 percentage injected dose per gram at 20 h after injection.

183 -PAS200 were applied (respective percentages injected dose per gram at 24 h after injection: 12.3 and

184 +/- 24.4 at 1 h to 2.13 +/- 1.36 percentage injected dose per gram at 24 h.

185 ors (19.0 +/- 3.6 vs. 2.7 +/- 1.6 percentage injected dose per gram at 3 and 69 h after injection, re

186 AR2-MMAE, reaching 119.7 +/- 37.4 percentage injected dose per gram at 3 d after injection.

187 .05, and 0.6+/-0.04 (mean +/- SD) percentage injected dose per gram at 30 min, 1.0 h, and 2.0 h after

188 .6 +/- 3.9, 28.6 +/- 6.0, and >35 percentage injected dose per gram at 4 h after injection, respectiv

189 8, 10.4 +/- 0.8, and 16.5 +/- 2.6 percentage injected dose per gram at 4, 24, and 48 h after injectio

190 negative A549 tumors (4.3 +/- 0.2 percentage injected dose per gram at 48 h after injection; n = 3).

191 itive HCC4006 tumors (9.4 +/- 0.5 percentage injected dose per gram at 48 h after injection; n = 4) a

192 tion and tumor uptake reached 4.2 percentage injected dose per gram by 20 min.

193 or uptake for 1F5(scFv)SA was 16.5% +/- 7.0% injected dose per gram compared with 2.3% +/- .9% inject

194 mor-specific uptake (13.0 and 8.5 percentage injected dose per gram for (64)Cu-SarAr-SA-Aoc-bombesin(

195 ion (16.5 +/- 2.8 and 8.6 +/- 1.3 percentage injected dose per gram for apoA-I- and phospholipid-labe

196 ted dose per gram compared with 2.3% +/- .9% injected dose per gram for the control FP.

197 phenotype, reaching at least 5.0 percentage injected dose per gram in all 3 tumor models.

198 HYNIC-28H1 uptake ranged from 1.5 percentage injected dose per gram in noninflamed joints to 22.6 per

199 ram in noninflamed joints to 22.6 percentage injected dose per gram in severely inflamed joints.

200 nce and uptake of approximately 8 percentage injected dose per gram in SKOV-3 tumors, with tumor-to-b

201 (1.24 +/- 0.07 vs. 0.57 +/- 0.08 percentage injected dose per gram in the unirradiated tumors; P < 0

202 characteristic curve analyses of percentage injected dose per gram measured from quantitative small-

203 n untreated atherosclerotic animals (percent injected dose per gram MPI uptake, 0.11 +/- 0.04%).

204 o, the hepatic tumors had a lower percentage injected dose per gram of (64)Cu-ATSM or -PTSM and more

205 hing the brain was approximately 0.2% of the injected dose per gram of brain tissue (ID/g).

206 (at 1 hour) and 34.3 +/- 12.7% (at 4 hours) injected dose per gram of LNCaP xenograft tissue, for [(

207 (18)F-RL-I-5F7 was 28.97 +/- 3.88 percentage injected dose per gram of tissue (%ID/g) at 1 h and 36.2

208 xenografts rose from less than 1 percentage injected dose per gram of tissue (%ID/g) to 14 %ID/g at

209 mpound [(68)Ga]3 demonstrated 3.78 +/- 0.90% injected dose per gram of tissue (%ID/g) within PSMA+ PI

210 ex vivo and expressed as a percentage of the injected dose per gram of tissue (%ID/g).

211 mice than in WT mice, measured as percentage injected dose per gram of tissue (P = 0.01).

212 cortex of TBI mice (1.15 +/- 0.53 percentage injected dose per gram of tissue [%ID/g]) than in the un

213 relatively constant from 18 h (5 percentage injected dose per gram of tissue [%ID/g]) to 48 h (3 %ID

214 rrow and spleen within 24 hours (18% and 79% injected dose per gram of tissue [ID/g], respectively),

215 I and (18)F-FDG was quantified by percentage injected dose per gram of tissue and normalized to total

216 lowed by a slower decrease to 4-5 percentage injected dose per gram of tissue at 1 h.

217 rapid brain washout (ratio of percentage of injected dose per gram of tissue at 2 and 30 min after i

218 Because of its high tumor uptake (90% injected dose per gram of tissue at 2 h postinjection) a

219 selective PIP tumor uptake, at 7.9 +/- 4.0% injected dose per gram of tissue at 30 min postinjection

220 e known brain distribution of sEH, with 5.2% injected dose per gram of tissue at peak uptake.

221 s of standardized uptake value or percentage injected dose per gram of tissue for absolute values; im

222 geting capability, with almost 10 percentage injected dose per gram of tissue in HER2-expressing tumo

223 The percentage injected dose per gram of tissue in the treated and cont

224 The percentage of the injected dose per gram of tissue was quantified for both

225 c fluid was 0.028 x 10(-5) %ID/g (percentage injected dose per gram of tissue) 50 days after administ

226 y (111)In-anti-gammaH2AX-TAT (defined as >5% injected dose per gram of tissue) was 96 d, compared wit

227 take was measured at 12.0 +/- 2.0 percentage injected dose per gram of tissue.

228 min after radiotracer injection (percentage injected dose per gram of tissue: 1.92 +/- 0.43 vs. 0.90

229 ted dose [ID] per gram of tissue vs 0.99% of injected dose per gram of tissue; P < .001).

230 was minimal (0.30 +/- 0.07 %ID/g [percentage injected dose per gram of tissue]); it increased signifi

231 ors than in A549 tumors, with percentages of injected dose per gram of tumor of 0.84 +/- 0.09 and 0.4

232 fter injection varied from 10% to 22% of the injected dose per gram of tumor tissue.

233 tumor vasculature at about 5% and 10% of the injected dose per gram organ (ID/g) for untargeted and R

234 in U87-stb-CXCR4 tumors, with the percentage injected dose per gram reaching a maximum of 102.70 +/-

235 ake was rapid, and there was 3.34 percentage injected dose per gram remaining at 60 min after injecti

236 Tumor uptake measured as percent of injected dose per gram tissue (%ID/g) at 3 hours was 4.3

237 though tumor uptake was low (0.65% +/- 0.04% injected dose per gram tissue [%ID/g]), it was still hig

238 d 4-F-T140 showed a 3.03 +/- 0.31 percentage injected dose per gram uptake in CHO-CXCR4 tumors, with

239 positive tumor cells (mean, ~0.05 percentage injected dose per gram) and in antigen-positive normal c

240 and showed good tumor uptake (10 percentage injected dose per gram) and retention and a greater than

241 ctive matriptase was high in xenografts (28% injected dose per gram) and was blocked in vivo by the a

242 racers, with low renal uptake (<4 percentage injected dose per gram) for (111)In-JVZ-007-cys already

243 , and the uptake of (18)F-SKI696 (percentage injected dose per gram) for each organ was calculated.

244 pecific tumor uptake (8.0 +/- 2.4 percentage injected dose per gram) in LNCaP tumor-bearing mice was

245 n demonstrated greater uptake (percentage of injected dose per gram) in tumors infected with Ad-HA-SS

246 Mean uptake (percentage injected dose per gram) of the dual-labeled tracer in tu

247 ptake at the target site (0.5-0.8 percentage injected dose per gram) that persisted over 5 h, produci

248 ol level of 0.61+/-0.17% ID/g (percentage of injected dose per gram) to 1.62+/-0.35% ID/g at postoper

249 y low uptake in most organs (<0.1 percentage injected dose per gram), and no evidence of blood-brain

250 of uptake in the tumor (4.1 +/- 0.3 percent injected dose per gram), coupled with the fecal excretio

251 ptake in M21 tumor (2.42 +/- 0.21 percentage injected dose per gram), fast renal excretion, and low b

252 The uptake in the liver (<0.5 percentage injected dose per gram), kidneys, and blood were similar

253 39, 5.24 +/- 0.29, 5.30 +/- 0.98 (percentage injected dose per gram), respectively.

254 15 was in the thrombus (1.0+/-0.2 percentage injected dose per gram), with low off-target accumulatio

255 68)Ga-IMP288 uptake (27.5 +/- 5.8 percentage injected dose per gram), with ratios of 13.6 +/- 4.8, 66

256 -TOC (5.2 +/- 0.2 vs. 3.6 +/- 0.4 percentage injected dose per gram).

257 ormal colonic mucosa (mean, ~0.03 percentage injected dose per gram).

258 tion and the measured PET signal (percentage injected dose per gram).

259 minent tumor uptake (27.7 +/- 7.6 percentage injected dose per gram).

260 skin concentration of liposomes (percent of injected dose per gram).

261 c-Met-negative MDA-MB-231 tumors (percentage injected dose per gram, 1.8 +/- 0.6 at 9 h after injecti

262 09 vs. 0.36 +/- 0.03, P < 0.0005; percentage injected dose per gram, 24 h: 3.24 +/- 0.65 vs. 1.63 +/-

263 F in c-Met-positive U87MG tumors (percentage injected dose per gram, 6.8 +/- 1.8 at 9 h after injecti

264 The tumor uptake was 1.1 +/- 0.3 percentage injected dose per gram, and the tumor-to-blood ratio was

265 entration in primary colon tumors was 0.016% injected dose per gram, compared with 0.004% in normal c

266 s as compared with the vena cava (percentage injected dose per gram, ctl: 21.4+/-6.1 vs. 10.0+/-3.9 v

267 (2.41 +/- 0.29 vs. 0.82 +/- 0.11 percentage injected dose per gram, P < 0.0001) was observed in L298

268 2A (16.9 +/- 2.2 vs. 13.4 +/- 1.7 percentage injected dose per gram, P = 0.07).

269 uptake at 2 min of 1.25 and 0.68 percentage injected dose per gram, respectively, and possessed high

270 s 2.15 +/- 0.55 and 1.24 +/- 0.26 percentage injected dose per gram, respectively.

271 19.6 +/- 4.50, and 14.4 +/- 1.63 percentage injected dose per gram, respectively.

272 tumors 4 h after injection was 10 percentage injected dose per gram, which was 2-fold higher than in

273 d was measured to be 13.7 +/- 1.8 percentage injected dose per gram.

274 (18)F-FDG uptake was expressed as percentage injected dose per gram.

275 on PET/CT images and expressed as percentage injected dose per gram.

276 , 5.35 +/- 0.22 and 5.30 +/- 0.20 percentage injected dose per gram; n = 3 and 4).

277 or uptake value (38 vs. 25 %ID/g [percentage injected dose per gram] for the control).

278 nd 60 min after tracer injection [percentage injected dose per gram]: 1.8 +/- 0.7, 1.2 +/- 0.1, and 0

279 ; and H1975, 12.1 +/- 3.5 maximal percentage injected dose per milliliter).

280 d 5.85 x 10(-8) +/- 5.95 x 10(-8) percentage injected dose per pixel for (99m)Tc-scVEGF and (99m)Tc-i

281 CLI measurements were radiance, radiance per injected dose (radiance/ID), and total radiant volume.

282 Mean urinary excretion was 4.83 percentage injected dose (range, 0.64-12.41 percentage injected dos

283 no significant difference in the percentage injected dose recovered in the urine at 30 min and at 3

284 clearance with only 26.2 +/- 6.1 percentage injected dose remaining in the carcass at 2 h, consisten

285 tage injected dose and 88.6+/-6.2 percentage injected dose, respectively, in urine at 10 min and 1 h

286 aging (2.2 +/- 0.4 vs. 1.4 +/- 0.3 cpm/mm(2)/injected dose, respectively, P < 0.05).

287 absolute gadolinium levels and percentage of injected dose, respectively.

288 All four imaging metrics (percentage of injected dose, SLN extraction, SLN uptake rate constant,

289 eted from the body at a higher percentage of injected dose than the nanorods at both the 7 and 28 day

290 As a percentage of injected dose, the levels of gadolinium measured were co

291 1 pmol, which represented 16.5%-64.1% of the injected dose; the amount of dye within the SLNs ranged

292 portunity to deliver a large fraction of the injected dose to insonified tumors and produce a complet

293 any other tracer we examined (61.8% +/- 9.6% injected dose vs. 29.4% +/- 9.5% for (64)Cu-ATSM, P < 0.

294 osttransplant days 7 and 42, and the percent injected dose was computed for each graft.

295 cumulate in tumours, whereas over 12% of the injected dose was recovered from the tumours of mice tre

296 d with any surfactants and a majority of the injected dose was taken up by the liver (>40%), while a

297 fluorescence in the blood pool (~40% of the injected dose) was similar for liposomes conjugated with

298 re were no system failures, and the error in injected doses when using automated injection was lower

299 n of all 3 tracers falling to less than 0.7% injected dose within 6 min.

300 (99m)Tc-HYNIC annexin V uptake as percentage injected dose (x10(-4)) decreased between days 1 and 7 b

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。